{"id":"diflucan-iv-oral","safety":{"commonSideEffects":[{"rate":"13","effect":"Headache"},{"rate":"7","effect":"Nausea"},{"rate":"6","effect":"Abdominal pain"},{"rate":"5","effect":"Diarrhea"},{"rate":"2","effect":"Rash"},{"rate":"1-3","effect":"Elevated liver enzymes"},{"rate":null,"effect":"QT prolongation"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluconazole is a triazole antifungal that selectively targets fungal sterol synthesis by inhibiting the enzyme lanosterol 14α-demethylase (CYP51). This prevents the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane, leading to membrane instability and fungal cell death. The drug has broad-spectrum activity against many Candida species, Cryptococcus, and other fungi.","oneSentence":"Diflucan (fluconazole) inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:51.751Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Candidiasis (oropharyngeal, esophageal, vaginal, systemic)"},{"name":"Cryptococcal meningitis"},{"name":"Fungal prophylaxis in immunocompromised patients"},{"name":"Coccidioidomycosis"}]},"trialDetails":[{"nctId":"NCT05421858","phase":"PHASE3","title":"A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.","status":"RECRUITING","sponsor":"Basilea Pharmaceutica","startDate":"2024-12-11","conditions":"Candidemia, Candidiasis, Invasive","enrollment":450},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT07395024","phase":"PHASE1","title":"A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2026-02-03","conditions":"Healthy Volunteer","enrollment":54},{"nctId":"NCT07044544","phase":"PHASE1","title":"Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-07-17","conditions":"Myeloid Malignancy, Hematologic Malignancy, Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT04368559","phase":"PHASE3","title":"Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mundipharma Research Limited","startDate":"2020-05-11","conditions":"Candidemia, Mycoses, Fungal Infection","enrollment":602},{"nctId":"NCT06666322","phase":"PHASE2, PHASE3","title":"Platform Trial For Cryptococcal Meningitis","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2025-05-28","conditions":"Hiv, Cryptococcal Meningitis","enrollment":2000},{"nctId":"NCT05178862","phase":"PHASE3","title":"A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole","status":"TERMINATED","sponsor":"Scynexis, Inc.","startDate":"2022-08-03","conditions":"Candidiasis, Invasive, Candidemia","enrollment":68},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT02244606","phase":"PHASE2","title":"Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis","status":"COMPLETED","sponsor":"Scynexis, Inc.","startDate":"2014-09","conditions":"Mycoses, Candidiasis, Invasive, Candidemia","enrollment":27},{"nctId":"NCT03667690","phase":"PHASE3","title":"Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis","status":"COMPLETED","sponsor":"Cidara Therapeutics Inc.","startDate":"2018-10-07","conditions":"Candidemia, Mycoses, Fungal Infection","enrollment":199},{"nctId":"NCT05541107","phase":"PHASE3","title":"Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3","status":"UNKNOWN","sponsor":"Matinas BioPharma Nanotechnologies, Inc.","startDate":"2023-01","conditions":"Cryptococcal Meningitis","enrollment":270},{"nctId":"NCT00000951","phase":"PHASE4","title":"A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent Thrush","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Candidiasis, Oral, HIV Infections","enrollment":948},{"nctId":"NCT04122560","phase":"PHASE4","title":"Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2019-11-30","conditions":"Fluconazole, Candidiasis, Invasive Fungal Infections","enrollment":25},{"nctId":"NCT02734862","phase":"PHASE2","title":"CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension","status":"COMPLETED","sponsor":"Cidara Therapeutics Inc.","startDate":"2016-07-26","conditions":"Candidemia, Mycoses, Fungal Infection","enrollment":207},{"nctId":"NCT00761267","phase":"PHASE3","title":"Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-02","conditions":"Candidemia","enrollment":70},{"nctId":"NCT00734539","phase":"PHASE3","title":"Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight","status":"COMPLETED","sponsor":"Daniel Benjamin","startDate":"2008-11","conditions":"Candidiasis","enrollment":362},{"nctId":"NCT01042704","phase":"PHASE1","title":"Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"Robert Redner, MD","startDate":"2008-02","conditions":"Myeloma","enrollment":29},{"nctId":"NCT00002533","phase":"PHASE2, PHASE3","title":"Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Miami","startDate":"1993-02","conditions":"Head and Neck Cancer, Infection, Oral Complications","enrollment":""},{"nctId":"NCT01176058","phase":"PHASE3","title":"A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treatment Of Patients With Candidemia And/Or Other Forms Of Invasive Candidiasis","status":"TERMINATED","sponsor":"Pfizer","startDate":"2010-12","conditions":"Candidemia","enrollment":17},{"nctId":"NCT01111942","phase":"EARLY_PHASE1","title":"A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer","status":"TERMINATED","sponsor":"Southern Illinois University","startDate":"2010-02","conditions":"Head and Neck Cancer","enrollment":4},{"nctId":"NCT00250718","phase":"PHASE2","title":"Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach","status":"TERMINATED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2004-10","conditions":"Non-Hodgkin's Lymphoma, Cancer","enrollment":17},{"nctId":"NCT00935363","phase":"PHASE1","title":"Interplay Between Organic Anion Transporting Polypeptide (OATP) Transporters Transporters and CYP2C9 in Glyburide Pharmacokinetics (PK)","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2010-02","conditions":"Healthy","enrollment":""},{"nctId":"NCT01974375","phase":"PHASE3","title":"Micafungin Versus Fluconazole for Prevention of Invasive Fungal Disease in Living Donor Liver Transplant Recipients","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2012-08","conditions":"Liver Transplant Recipient","enrollment":172},{"nctId":"NCT00496197","phase":"PHASE4","title":"Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-07","conditions":"Candidiasis","enrollment":282},{"nctId":"NCT00163111","phase":"PHASE3","title":"A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood.","status":"COMPLETED","sponsor":"Pfizer","startDate":"1998-09","conditions":"Candidiasis","enrollment":412}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Diflucan IV, oral","genericName":"Diflucan IV, oral","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Diflucan (fluconazole) inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane. Used for Candidiasis (oropharyngeal, esophageal, vaginal, systemic), Cryptococcal meningitis, Fungal prophylaxis in immunocompromised patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}